Mar 15, 2022 4:05pm EDT Sapience Therapeutics to Participate at SVB Leerink Biopharma Private Company Connect
Mar 09, 2022 8:00am EST Sapience Therapeutics Announces Multiple Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022
Feb 15, 2022 8:00am EST Sapience Therapeutics Strengthens Executive Team with Appointments of Marisa Frackman as Chief Financial Officer and Seth I. Rubin as General Counsel
Feb 03, 2022 4:05pm EST Sapience Therapeutics to Present at Guggenheim Healthcare Talks, 2022 Oncology Conference
Jan 06, 2022 8:00am EST Sapience Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ST101
Dec 15, 2021 8:16am EST Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for Advanced Cutaneous Melanoma
Dec 09, 2021 8:00am EST Sapience Therapeutics Announces Multiple Poster Presentations on ST101 at the 2021 San Antonio Breast Cancer Symposium
Dec 06, 2021 8:00am EST Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for the Treatment of Recurrent Glioblastoma Multiforme (GBM)
Dec 01, 2021 4:05pm EST Sapience Therapeutics to Present at the RBC Capital Markets Healthcare Private Company Conference
Nov 10, 2021 4:05pm EST Sapience Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference
